Articles tagged "Graft arterlosclerosis"

2020 American Transplant Congress
Age-Enhanced Transplant Vasculopathy Associates with Impaired Vascular Mitophagy
M. Blin¹, D. Tyrrell¹, S. Wood¹, D. Farris¹, S. G. Tullius², D. R. Goldstein¹
¹Micro and Immunology/Internal Medicine, University of Michigan, Ann Arbor, MI, ²Transplant Surgery, Brigham and Women's Hospital, Boston, MA
*Purpose: Donor aging leads to increased chronic allograft vasculopathy (CAV) for unclear reasons. Here, we investigated whether impaired alterations in mitophagy, a mechanism to remove…
2020 American Transplant Congress
Impact of Alemtuzumab Induction on Cardiac Allograft Vasculopathy in Orthotopic Heart Transplant Recipients
M. Plazak¹, X. Gao², S. Gale², B. Reed², R. Madathil¹, S. Hammad¹, B. Ravichandran¹
¹University of Maryland Medical Center, Baltimore, MD, ²University of Maryland School of Pharmacy, Baltimore, MD
*Purpose: Cardiac allograft vasculopathy (CAV) is impacted by acute rejection and ultimately limits long-term survival of orthotopic heart transplant (OHT) recipients, thus there is interest…
2020 American Transplant Congress
Impact of Statin Intensity on the Development of Cardiac Allograft Vasculopathy
K. Goehring¹, W. Kuan¹, A. Sieg¹, K. L. Dawson¹, A. R. Kolodziej²
¹Department of Pharmacy, University of Kentucky HealthCare, Lexington, KY, ²Gill Heart and Vascular Institute, University of Kentucky HealthCare, Lexington, KY
*Purpose: This study aims to examine the efficacy of high-intensity statin therapy compared to low-intensity, moderate-intensity, or no statins at preventing cardiac allograft vasculopathy (CAV)…
2020 American Transplant Congress
Taking it to the Max: Extremely Low LDL May Provide Benefit for Prevention of Cardiac Allograft Vasculopathy
R. Lee¹, E. J. Henricksen¹, Y. Moayedi², K. Y. Feng³, J. Han³, W. Yang⁴, R. Imai¹, J. J. Teuteberg⁴, K. K. Khush⁴
¹Pharmacy, Stanford Health Care, Stanford, CA, ²University Health Network, Toronto, ON, Canada, ³Medicine, Stanford University, Stanford, CA, ⁴Cardiac Transplant, Stanford University, Stanford, CA
*Purpose: Routine use of statins is the only Class I ISHLT recommendation in heart transplantation (HT) to reduce cardiac allograft vasculopathy (CAV) and improve survival.…
2020 American Transplant Congress
Regulatory T Cell-Derived Amphiregulin Activates Fibroblasts to Promote Chronic Rejection after Heart Transplantation
L. Fan¹, X. Zhang¹, T. Li¹, L. R. Mathews¹, G. K. Dwyer², M. J. Calderon³, K. E. Helfrich³, M. A. Ross³, S. C. Watkins³, H. R. Turnquist¹
¹Surgery, University of Pittsburgh, Pittsburgh, PA, ²Immunology, University of Pittsburgh, Pittsburgh, PA, ³Center for Biologic Imaging, University of Pittsburgh, Pittsburgh, PA
*Purpose: Chronic rejection (CR) after organ transplantation (Tx) manifests as function-limiting allograft fibrosis and vasculopathy. Current immunosuppressants fail to prevent CR and insights into the…
2019 American Transplant Congress
Identification and Determinants of Cardiac Allograft Vasculopathy Trajectories after Heart Transplantation
G. Bonnet¹, G. Coutance¹, M. Racape¹, M. Raynaud¹, J. Van keer², M. Bories¹, S. Varnous³, P. Rouvier³, R. Guillemain⁴, L. Lecuyer⁴, P. Bruneval⁴, J. Duong-Van-Huyen¹, J. Taupin⁵, M. Naesens², C. Lefaucheur¹, X. Jouven¹, A. Loupy¹
¹Paris Transplant Group, Paris, France, ²KU Leuven, Leuven, France, ³Pitie Salpetriere Hospital, Paris, France, ⁴Georges Pompidou Hospital, Paris, France, ⁵Saint Louis Hospital, Paris, France
*Purpose: CAV is a major contributor of heart transplant recipient’s mortality. However, little is known about CAV long-term evolution profiles and their determinants. Such information…
2019 American Transplant Congress
Clonal Composition And Single-cell Characterization Of T-cell Infiltrates In Cardiac Allograft Vasculopathy
M. V. Habal¹, A. Myung², H. Yan², S. Rao², S. Lin², S. See², P. Roy², R. Shihab², C. Marboe³, S. Restaino¹, A. Han², M. Givertz⁴, J. C. Madsen⁵, L. Addonizio¹, M. Farr¹, E. Zorn²
¹Cardiology, Columbia University Medical Center, New York, NY, ²Columbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, ³Pathology, Columbia University Medical Center, New York, NY, ⁴Cardiology, Brigham and Women's Hospital, Boston, MA, ⁵Surgery, Massachusetts General Hospital, Boston, MA
*Purpose: T-cells are implicated in the pathogenesis of cardiac allograft vasculopathy (CAV), yet their clonal composition and function are incompletely defined. We examined the T-cell…
2019 American Transplant Congress
Long-Term Influence of Arteriosclerosis in Kidney Grafts Proven by a Zero-Hour Biopsy
Y. Kakuta¹, M. Okumi¹, T. Kanzawa¹, K. Unagami², H. Ishida¹, K. Tanabe¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Organ Transplant Medicine, Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Histopathological assessment of kidney grafts by zero-hour biopsies adds unique information concerning organ quality that is not available on clinical grounds. The most prevalent…
2019 American Transplant Congress
HbA1c as a Noninvasive Predictor of Chronic Histopathologic Changes in Living Donors for Kidney Transplantation
K. Tanaka¹, S. Nishida¹, K. Kinoshita¹, Y. Hidaka¹, M. Toyoda², A. Inadome³, A. Takeda⁴, H. Yokomizo⁵, S. Uekihara⁶, J. Shoji⁷, S. Yamanaga¹
¹Surgery, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, ²general medicine, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, ³Urology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, ⁴Nephrology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan, ⁵Surgery, Japanese Red Cross Kumamoto Hospital, kumamoto, Japan, ⁶general medicine, Japanese Red Cross Kumamoto Hospital, kumamoto, Japan, ⁷Nephrology, UCSF Connie Frank Transplant Center, San francisco, CA
*Purpose: The degree of chronic histopathologic changes in renal allografts, including interstitial fibrosis, tubular atrophy, and arteriolar hyalinosis, can have clinical implications in long-term allograft…
2018 American Transplant Congress
Upregulated IL-33 in Heart Transplants Modulates Local Myeloid Populations to Protect against Chronic Allograft Rejection
Z. Zhang,¹ Q. Liu,¹ G. Hussey,² J. Dziki,² L. Mathews,¹ H. Dai,¹ G. Dwyer,^1,3 A. Lucas,¹ M. Oberbarnscheidt,¹ S. Badylak,² H. Turnquist.^1,3
¹University of Pittsburgh, Starzl Transplant Institute, Pittsburgh, PA; ²University of Pittsburgh, McGowan Institute for Regenerative Medicine, Pittsburgh, PA; ³Immunology, University of Pittsburgh, Pittsburgh, PA.
Purpose: Interleukin-33 (IL-33) is an “alarmin”, or a self-derived molecule that triggers pleotropic immune responses after release from damaged tissue. Yet, how IL-33 shapes alloresponses…